Recent identification of markers of immunotherapy (PD1, PD-L1, microsatellite instability, and mutation burden) in ACC led to clinical trials with immune checkpoint inhibitors (pembrolizumab, nivolumab, avelumab, and ipilimumab) for advanced ACC patients. This evidence concerns the gene CD274 and adrenal cortex carcinoma.